Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.

Gal TsabanHilmi AlnsasraAref El NasasraAmjad Abu-SalmanAla Abu-DogoshItay WeissbergYael Ben-Baruch GolanOrit BarrettRoi WestreichEnis AboalhasanJoseph AzuriAriel HammermanRonen Arbel

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)

Combining aspirin with LD rivaroxaban provides better value for money than with LD ticagrelor for secondary prevention of MACE.

Keyphrases

low dose
acute coronary syndrome
percutaneous coronary intervention
venous thromboembolism
atrial fibrillation
antiplatelet therapy
high dose
pulmonary embolism
st segment elevation myocardial infarction
st elevation myocardial infarction
coronary artery disease